SCHEMBL155502

SCHEMBL155502

CCCC[Sn](CCCC)(CCCC)c1cncnc1

nearest known ligand 0.31

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 1/20 0.31
HDAC3 O15379 1/20 0.31
HDAC1 Q13547 1/20 0.31
HDAC2 Q92769 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1180513 0.77
SCHEMBL29851135 0.76 L3MBTL1 (0.49) HDAC3HDAC1HDAC2
SCHEMBL5733424 0.76 HCAR2 (0.32)
SCHEMBL154603 0.76 L3MBTL1 (0.49) HDAC3HDAC1HDAC2
SCHEMBL7002113 0.75 NPC1 (0.32)
SCHEMBL1763594 0.75 PKM (0.33)
SCHEMBL12502235 0.75 CHRNB2 (0.33)
SCHEMBL4069966 0.75 HCAR2 (0.32)
SCHEMBL658276 0.74 CYP2D6 (0.41) HDAC3HDAC1HDAC2
SCHEMBL1983658 0.74 TSHR (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 207 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140221639-A1 RADIOLABELED NUCLEOSIDE ANALOGUE, AND PREPARATION METHOD AND USE THEREOF INSTITUTE OF NUCLEAR ENERGY RESEARCH ATOMIC ENERGY COUNCIL, EXECUTIVE YUAN (TW) 2014-08-07 US claimed
US-20120178919-A1 RADIOLABELED NUCLEOSIDE ANALOGUE, AND PREPARATION METHOD AND USE THEREOF NATIONAL YANG-MING UNIVERSITY (TW) 2012-07-12 US claimed
WO-2025110699-A1 NOVEL COMPOUND AND USE THEREOF 주식회사 프로티어바이오텍 2025-05-30 WO disclosed
US-20240208952-A1 THIOPHENE GLP-1 RECEPTOR AGONIST AND USE THEREOF HANGZHOU ZHONGMEIHUADONG PHARMACEUTICAL CO., LTD. (CN) 2024-06-27 US disclosed
US-20240109900-A1 AZABICYCLIC SHP2 INHIBITORS PROMIDIS S.R.L. (IT) 2024-04-04 US disclosed
EP-4317142-A1 THIOPHENE GLP-1 RECEPTOR AGONIST AND USE THEREOF Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. (CN) 2024-02-07 EP disclosed
EP-4288431-A1 AZABICYCLIC SHP2 INHIBITORS IRBM S.P.A. (IT) 2023-12-13 EP disclosed
CN-116940561-A Thiophene GLP-1 receptor agonist and application thereof 杭州中美华东制药有限公司 2023-10-24 CN disclosed
US-11787890-B2 High performance and recyclable thermoset ink for 3D or 4D printing BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) 2023-10-17 US disclosed
US-20220403080-A1 HIGH PERFORMANCE AND RECYCLABLE THERMOSET INK FOR 3D OR 4D PRINTING BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) 2022-12-22 US disclosed
US-20220389007-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) 2022-12-08 US disclosed
EP-0783499-A1 BENZOFURAN DERIVATIVES AS TACHYKININ ANTAGONISTS GLAXO GROUP LIMITED (GB) 1997-07-16 EP disclosed
US-5502065-A TREATING HEADACHES PFIZER INC. (US) 1996-03-26 US disclosed
WO-1995006645-A1 BENZOFURAN DERIVATIVES AS TACHYKININ ANTAGONISTS GLAXO GROUP LIMITED (GB) 1995-03-09 WO disclosed
EP-0636129-A1 INDOLE DERIVATIVES AS 5-HT1-LIKE AGONISTS Pfizer Limited (GB) 1995-02-01 EP disclosed
US-5380730-A Angiotensin antagonist IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1995-01-10 US disclosed
CN-1082040-A Indoles PFIZER RES & DEV (IE) 1994-02-16 CN disclosed
WO-1993021178-A1 INDOLE DERIVATIVES AS 5-HT1-LIKE AGONISTS PFIZER LIMITED (GB) 1993-10-28 WO disclosed
US-5236936-A Treating hypertension, congestive heart failure IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1993-08-17 US disclosed
EP-0499416-A2 Pyridine compounds as angiotensin II antagonists, processes for their preparation and pharmaceutical compositions containing them ZENECA LIMITED (GB) 1992-08-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220389007-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION EIF2AK2, POLR2E, POLR2H HRH3 2905/4885HDAC3 2376/4885HDAC1 488/4885
US-20240109900-A1 AZABICYCLIC SHP2 INHIBITORS PTPN22, PTPN2, PTPN5 HRH3 4743/4885HDAC3 474/4885HDAC1 153/4885
US-20120178919-A1 RADIOLABELED NUCLEOSIDE ANALOGUE, AND PREPARATION METHOD AND USE THEREOF TYMP, TK1, NUDT1 HRH3 2969/4885HDAC3 4824/4885HDAC1 4175/4885
US-20140221639-A1 RADIOLABELED NUCLEOSIDE ANALOGUE, AND PREPARATION METHOD AND USE THEREOF TYMP, TK1, NUDT1 HRH3 2969/4885HDAC3 4824/4885HDAC1 4175/4885
US-20240208952-A1 THIOPHENE GLP-1 RECEPTOR AGONIST AND USE THEREOF GLP1R, GIPR, GCGR HRH3 2144/4885HDAC3 4010/4885HDAC1 3158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.